[1] Josephson CB, Jetté N. Psychiatric comorbidities in epilepsy[J]. Int Rev Psychiatry, 2017, 29:409-424. [2] López González FJ, Rodríguez Osorio X, Gil-Nagel Rein A, Carreño Martínez M, Serratosa Fernández J, Villanueva Haba V, Donaire Pedraza AJ, Mercadé Cerdá JM. Drug-resistant epilepsy:definition and treatment alternatives[J]. Neurologia, 2015, 30:439-446. [3] Pitkänen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets[J]. Lancet Neurol, 2011, 10:173-186. [4] Korotkov A, Broekaart DWM, Banchaewa L, Pustjens B, van Scheppingen J, Anink JJ, Baayen CJ, Idema S, Gorter AJ, van Vliet AEJ, Aronica E. micorRNA-132 is overexpressed in glia in temporal lobe epilepsy and reduces the expression of proepileptogenic factors in human cultured astrocytes[J]. Glia, 2020, 68:60-75. [5] Baloun J, Bencurova P, Totkova T, Kubova H, Hermanova M, Hendrych M, Pail M, Pospisilova S, Brazdil M. Epilepsy miRNA profile depends on the age of onset in humans and rats[J]. Front Neurosci, 2020, 14:924. [6] Gilad D, Shorer S, Ketzef M, Friedman A, Sekler I, Aizenman E, Hershfinkel M. Homeostatic regulation of KCC2 activity by the zinc receptor mZnR/GPR39 during seizures[J]. Neurobiol Dis, 2015, 81:4-13. [7] Racine RJ. Modification of seizure activity by electrical stimulation. Ⅱ:motor seizure[J]. Electroencephalogr Clin Neurophysiol, 1972, 32:281-294. [8] Reyes-Garcia SZ, Scorza CA, Araújo NS, Ortiz-Villatoro NN, Jardim PA, Centeno R, Yacubian TME, Faber J, Cavalheiro AE. Different patterns of epileptiform-like activity are generated in the sclerotic hippocampus from patients with drug-resistant temporal lobe epilepsy[J]. Sci Rep, 2018, 8:7116. [9] Sherstyuk VV, Medvedev SP, Elisaphenko EA, Vaskova EA, Ri MT, Vyatkin YV, Saik OV, Shtokalo DN, Pokushalov EA, Zakian SM. Genome-wide profiling and differential expression of microRNA in rat[J]. Sci Rep, 2017, 7:2787. [10] Brennan GP, Henshall DC. microRNAs in the pathophysiology of epilepsy[J]. Neuroscience letters, 2017, 8:15-20. [11] Hu K, Xie Y, Zhang C, Ouyang DS, Long HY, Sun DN, Long LL, Feng L, Li Y, Xiao B. MicroRNA expression profile of the hippocampus in a rat model of temporal lobe epilepsy and miR-34a-targeted neuroprotection against hippocampal neurone cell apoptosis post-status epilepticus[J]. BMC Neurosci, 2012, 13:115. [12] Li MM, Jiang T, Sun Z, Zhang Q, Tan CC, Yu JT, Tan L. Genome-wide microRNA expression profiles in hippocampus of rats with chronic temporal lobe epilepsy[J]. Sci Rep, 2014, 4:4734. [13] Ashhab MU, Omran A, Gan N, Kong H, Peng J, Yin F. microRNAs (9, 138, 181A, 221, and 222) and mesial temporal lobe epilepsy in developing brains[J]. Transl Neurosci, 2013, 4:357-362. [14] Miller-Delaney SF, Bryan K, Das S, Bray IM, Reynolds JP, Gwinn R, Stallings RL, Henshall DC. Differential DNA methylation profiles of coding and non-coding genes define hippocampal sclerosis in human temporal lobe epilepsy[J]. Brain, 2015, 138:616-631. [15] Chen J, Liu C, Xu M, Zhu J, Xia Z. Upregulation of miR-19b-3p exacerbates chronic stress-induced changes in synaptic plasticity and cognition by targeting Drebrin[J]. Neuropharmacology, 2022, 207:108951. [16] Davis CM, Bah TM, Zhang WH, Nelson JW, Golgotiu W, Nie X, Alkayed FN, Young JM, Woltjer RL, Silbert LC, Grafe MR, Alkayed NJ. GPR39 localization in the aging human brain and correaltion of expression and polymorphism with vascular cognitive impairment[J]. Alzheimers Dement (NY), 2021, 7:12214. [17] Yang D, Zhou Q, Labroska V, Qin S, Darbalaei S, Wu Y, Yuliantie E, Xie L, Tao H, Cheng J, Liu Q, Zhao S, Shui W, Jiang Y, Wang MW. G protein-coupled receptors:structure-and function-based drug discovery[J]. Signal Transduct Target Ther, 2021, 6:7. [18] Młyniec K, Trojan E, Ślusarczyk J, Głombik K, Basta-Kaim A, Budziszewska B, Skrzeszewski J, Siwek A, Holst B, Nowak G. Immune malfunction in the GPR39 zinc receptor of knockout mice:its relationship to depressive disorder[J]. J Neuroimmunol, 2016, 291:11-17. [19] Jackson VR, Nothacker HP, Civelli O. GPR39 receptor expression in the mouse brain[J]. Neuroreport, 2006, 17:813-816. [20] Myniec K, Doboszewska U, Szewczyk B, Sowa-Kućma M, Misztak P, Piekoszewski W, Trela F, Ostachowicz B, Nowak G. The involvement of the GPR39-Zn(2+)-sensing receptor in the pathophysiology of depression:studies in rodent models and suicide victims[J]. Neuropharmacology, 2014, 79:290-297. [21] Besser L, Chorin E, Sekler I, Silverman WF, Atkin S, Russell JT, Hershfinkel M. Synaptically released zinc triggers metabotropic signaling via a zinc-sensing receptor in the hippocampus[J]. J Neurosci, 2009, 29:2890-2901. [22] Mo F, Tang Y, Du P, Shen Z, Yang J, Cai M, Zhang Y, Li H, Shen H. GPR39 protects against corticosterone-induced neuronal injury in hippocampal cells through the CREB-BDNF signaling pathway[J]. J Affect Disord, 2020, 272:474-484. |